Substudy A and Substudy B Interim Report – 6-Month Safety Final Analysis: A Phase 2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b2 RNA-Based Vaccine Candidates for SARS-CoV-2 New Variants in Healthy Individuals

Substudy A and Substudy B Interim Report – 6-Month Safety Final Analysis: A Phase 2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b2 RNA-Based Vaccine Candidates for SARS-CoV-2 New Variants in Healthy Individuals chavak11 Thu, 03/05/2026 - 04:25 Comirnaty® PF-07302048 (BNT162b2) PHASE II/III Thu, 08/10/2023 - 12:00 Fri, 03/22/2024 - 12:00 NCT05997290 C4591054 SSA SSB 6MPD Safety Interim Public Disclosure Synopsis .pdf (131.79 KB) N https://clinicaltrials.gov/study/NCT05997290?term=C4591054&rank=1 C4591054